- Home
- GFAI vs TOVX Comparison
GFAI vs TOVX Comparison
Compare GFAI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- TOVX
- Stock Information
- Founded
- GFAI 2018
- TOVX 2001
- Country
- GFAI Singapore
- TOVX United States
- Employees
- GFAI N/A
- TOVX N/A
- Industry
- GFAI Diversified Commercial Services
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- TOVX Health Care
- Exchange
- GFAI Nasdaq
- TOVX Nasdaq
- Market Cap
- GFAI 12.5M
- TOVX 3.5M
- IPO Year
- GFAI N/A
- TOVX 2006
- Fundamental
- Price
- GFAI $1.09
- TOVX $1.14
- Analyst Decision
- GFAI Strong Buy
- TOVX Strong Buy
- Analyst Count
- GFAI 2
- TOVX 1
- Target Price
- GFAI $6.75
- TOVX $6.00
- AVG Volume (30 Days)
- GFAI 1.8M
- TOVX 96.3K
- Earning Date
- GFAI 12-27-2024
- TOVX 11-12-2024
- Dividend Yield
- GFAI N/A
- TOVX N/A
- EPS Growth
- GFAI N/A
- TOVX N/A
- EPS
- GFAI N/A
- TOVX N/A
- Revenue
- GFAI $35,841,743.00
- TOVX N/A
- Revenue This Year
- GFAI $0.37
- TOVX N/A
- Revenue Next Year
- GFAI $5.60
- TOVX N/A
- P/E Ratio
- GFAI N/A
- TOVX N/A
- Revenue Growth
- GFAI 1.78
- TOVX N/A
- 52 Week Low
- GFAI $0.94
- TOVX $1.14
- 52 Week High
- GFAI $4.30
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- GFAI 42.23
- TOVX 36.15
- Support Level
- GFAI $1.20
- TOVX $1.23
- Resistance Level
- GFAI $1.35
- TOVX $1.21
- Average True Range (ATR)
- GFAI 0.19
- TOVX 0.07
- MACD
- GFAI -0.04
- TOVX 0.01
- Stochastic Oscillator
- GFAI 18.74
- TOVX 0.00
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.